GSA Capital Partners LLP Buys Shares of 49,145 Arcturus Therapeutics Holdings Inc. $ARCT

GSA Capital Partners LLP bought a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 49,145 shares of the biotechnology company’s stock, valued at approximately $330,000.

Several other hedge funds have also modified their holdings of ARCT. AQR Capital Management LLC bought a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at about $128,000. Millennium Management LLC purchased a new position in shares of Arcturus Therapeutics in the 1st quarter worth approximately $4,892,000. Goldman Sachs Group Inc. grew its position in shares of Arcturus Therapeutics by 9.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after buying an additional 42,636 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Arcturus Therapeutics during the 1st quarter worth approximately $701,000. Finally, Strs Ohio bought a new position in shares of Arcturus Therapeutics during the 1st quarter worth approximately $89,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ARCT has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $13.45 on Friday. The stock has a 50-day moving average of $7.09 and a two-hundred day moving average of $7.49. Arcturus Therapeutics Holdings Inc. has a one year low of $5.50 and a one year high of $24.17. The stock has a market cap of $382.25 million, a PE ratio of -4.06 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The business had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. As a group, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.48 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.